How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of trabeculectomy with a biodegradable collagen matrix implant for glaucoma

    Closed for comments This consultation ended on at   Request commenting lead permission

    Additional information considered by IPAC

    Professional experts' opinions

    Expert advice was sought from consultants who have been nominated or ratified by their professional Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by professional experts, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, when comments are considered voluminous, or publication would be unlawful or inappropriate. One professional expert questionnaire for trabeculectomy with a biodegradable collagen matrix implant for glaucoma were submitted and can be found on the NICE website.

    Patient commentators' opinions

    NICE's Public Involvement Programme will send questionnaires to NHS trusts for distribution to patients who had the procedure (or their carers). When NICE has received the completed questionnaires, these will be discussed by the committee.

    Company engagement

    A structured information request was sent to 1 company who manufacture a potentially relevant device for use in this procedure. NICE received 1 completed submission. This was considered by the IP team and any relevant points have been taken into consideration when preparing this overview.

    Issues for consideration by IPAC

    • The biodegradable collagen matrix implant contains animal (porcine) collagen and may not be acceptable to those with certain religious beliefs or strict vegetarians or those with known allergy to the material.

    • Omnigen human amniotic membrane-derived matrix (referred by the specialist adviser) is different from the porcine collagen implant (Ologen) and therefore has not been considered in this IP overview.

    • Studies on paediatric, congenital and juvenile glaucoma are not considered in this review.